New book list for the week of 1/27/09

The new books are in, come and check them out!

• HD58.8 .K65 1996
  Leading change
  Kotter, John P., 1947-
• JC330.3 .G37 1990
  On leadership
  Gardner, John W. (John William), 1912-2002.
• QH431 .R475 1999
  Genome : the autobiography of a species in 23 chapters
  Ridley, Matt.
• QH450 .E977 2007
  Expression systems: methods express
  Dyson, Michael.
• QL668 .E265 S55 2000
  Early development of Xenopus laevis : a laboratory manual
  Sive, Hazel L.
• R853 .H8 O96 2008
  The Oxford textbook of clinical research ethics
• R858 .I59 2007
  Investing in E-health : what it takes to sustain consumer health informatics
  Gustafson, David H
• RA395.A3.H395 2008
  Jonas and Kovner’s health care delivery in the United States
  Kovner, Anthony R.
  Emanuel, Ezekiel J., 1957-
• RA645 .35 .H66 2007
  Home-centered health care : the Populist transformation of the American health care system
  Magee, Mike, M.D.
• RA971 .33 E38 2008
  eBusiness in healthcare : from eProcurement to supply chain management
  Hubner, Ursula, Ph. D.
• RB127 .P332265 2007
  Pain in older people
  Crome, Peter.
• RC280.H4 H3847
  Head and neck cancer : an evidence-based team approach
  Genden, Eric M.
• RC280.P7 T737 2008
  Treatment methods for early and advanced prostate cancer
  Kirby, R. S. (Roger S.)
• RC280 .U74 U777 2008
  Urological oncology
  Nargund, Vinod H.
• RC281 .W65 C3738 2008
  Crazy sexy cancer survivor : more rebellion and fire for your healing journey
  Carr, Kris.
• RC281 .W65 C374 2007
  Crazy sexy cancer tips
  Carr, Kris.
• TK5105.888 .K5546 2008
  Designing the digital experience : how to use experience design tools and techniques to build Websites customers love
  King, David Lee, 1966-
• Z6658 .I54 2008
  Introduction to reference sources in the health sciences
  Huber, Jeffrey T.

Come see us!

Come see us (and bring your books)

Now that the West Building book drop is gone, come to the library to bring back your books. While you’re here, grab a cup of coffee (or hot chocolate) and read the paper. Ask us a question. Check your email. There are lots of things you can do in the library.

Degarelix approved by the FDA

from MDConsult:

ST LOUIS (MD Consult) – The US Food and Drug Administration (FDA) has approved the injectable drug degarelix, the first new drug in several years for prostate cancer.

Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of prostate cancer by suppressing testosterone, which plays an important role in the continued growth of prostate cancer.

Hormonal treatments for prostate cancer may cause an initial surge in testosterone production before lowering testosterone levels. This initial stimulation of the hormone receptors may temporarily prompt tumor growth rather than inhibiting it. Degarelix doesn’t do this.

“Prostate cancer is the second leading cause of cancer death among men in the United States, and there is an ongoing need for additional treatment options for these patients,” said Richard Pazdur, MD, director of the Office of Oncology Drug Products, Center for Drug Evaluation and Research, FDA.

Prostate cancer is one of the most commonly diagnosed cancers in the United States. In 2004, the most recent year for which statistics are available, nearly 190,000 men were diagnosed with prostate cancer, and 29,000 men died from the cancer.

Several treatment options exist for different stages of prostate cancer, including observation, prostatectomy (surgical removal of the prostate gland), radiation therapy, chemotherapy, and hormone therapy with agents that affect GnRH receptors.

The efficacy of degarelix was established in a clinical trial in which patients with prostate cancer received either degarelix or leuprolide, a drug currently used for hormone therapy in treating advanced prostate cancer. Degarelix treatment did not cause the temporary increase in testosterone that is seen with some other drugs that affect GnRH receptors.

In fact, nearly all the patients on either drug had suppression of testosterone to levels seen with surgical removal of the testes.

The most frequently reported adverse reactions in the clinical study included injection-site reactions (pain, redness, and swelling), hot flashes, increased weight, fatigue, and increases in some liver enzymes.

Degarelix is manufactured for Ferring Pharmaceuticals Inc, Parsippany, NJ, by Rentschler Biotechnologie Gmbh, Laupheim, Germany.

New journal titles!

The Talbot Research Library is pleased to announce the addition of four electronic titles to the Library’s collection. These titles are: Clinical Genetics, Journal of Cancer Education, Genetic Testing, and Journal of Proteome Research. Access to these titles is available on the Journal Holdings list on the library’s website.

The aim of Clinical Genetics is to link research to the clinic in the understanding of the molecular basis of genetic disease. It is indexed in Medline (Pubmed) and Web of Science. The online subscription goes back to 1998 and print holdings go back to 1980.

The Journal of Cancer Education is the official journal of the American Association for Cancer Education (AACE) and the European Association for Cancer Education (EACE). It is indexed in medline (pubmed), psycInfo, and CINAHL and published quarterly. The subscription allows access back to 2003 and the library has print holdings from 1996-1999.

Genetic Testing is a resource for those who develop, perform, and interpret genetic tests and their results. The subscription allows access back to 1999, and it is indexed in Medline (Pubmed) and Web of Science.

The Journal of Proteome Research is a fairly new journal from ACS Publications (American Chemical Society) that encompasses all aspects of global protein analysis. It has an impressive impact factor of 5.675 and is indexed in Medline (Pubmed), Web of Science, and CAS database interfaces, including SCIFINDER. The electronic subscription includes the entire journal contents starting in 2002.

New books for the week of January 12th

Please visit or call (x2711) if you’re interested in checking out one of our new books!

• QH467 .D164 2007
  DNA repair, genetic instability, and cancer
  Wei, Qingyi.
• QP517 .C45 K73 2008
  Biochemistry of signal transduction and regulation
  Krauss, Gerhard.
• RC268.4 .B869 2008
  Principles of cancer genetics
  Bunz, Fred.
• RC646 .I58 2008
  Ioachim’s lymph node pathology
  Ioachim, Harry L., 1924-
• RC952.5 .P39 2007
  Patient falls assessment and prevention : strategies and tools to comply with JCAHO
  Payson, Carol A

Special librarians make the cut

U.S. News and World Report ranks librarianship as one the best careers for 2009. Special librarians are needed in all sorts of research organizations, such as Fox Chase, as well as law firms, pharmaceutical companies, non-profit agencies, hospitals and more. Librarians have to go through extensive graduate training and do not simply shelve books:

Forget about that image of librarians as a mousy bookworms. More and more of today’s librarians must be clever interrogators, helping the patron to reframe their question more usefully. Librarians then become high-tech information sleuths, helping patrons plumb the oceans of information available in books and digital records, often starting with a clever Google search but frequently going well beyond.

See the entire article here.